Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach

Abstract

Purpose: Telotristat etiprate, a tryptophan hydroxylase inhibitor, was previously evaluated in a Phase II randomized, placebo-controlled clinical trial in patients with carcinoid syndrome (CS) and diarrhea not adequately controlled by octreotide. The objective of the current study was to characterize the symptom experiences of patients participating in that trial.

Methods: Consenting patients participated in one-on-one, qualitative interviews focused on eliciting symptoms they had experienced in association with their CS diagnosis and recollection of symptom changes they experienced while participating in the Phase II trial.

Findings: Among the 23 patients who participated in the previous 4-week dose-escalation study, 16 were eligible for interviews and 11 participated in the present study. The median time from study completion to the interview was 31 months; 4 of 11 patients were receiving telotristat etiprate in a follow-up, open-label trial at the time of interview. All of the patients (100%) described diarrhea as a symptom of CS, with effects on the emotional, social, and physical aspects of their lives. Improvement in diarrhea during the study was described by 82% of participants, and was very impactful in several patients. Results led to the design and implementation of a larger interview program in Phase III and helped to establish a definition of clinically meaningful change for the clinical development program.

Implications: The diarrhea associated with CS can have a large impact on daily lives, and patient interviews can characterize and capture clinically meaningful improvements with treatment. ClinicalTrials.gov Identifier: NCT00853047.

Keywords: carcinoid syndrome; patient-reported; qualitative; telotristat etiprate.

Conflict of interest statement

CONFLICTS OF INTEREST

This study and its publication were funded in full by Lexicon Pharmaceuticals, Inc, the developers of telotristat etiprate.

M.H. Kulke has served as a paid consultant to Lexicon Pharmaceuticals. Q.M. Yang, S. Jackson, K.A. Boehm, and P. Lapuerta are employees of, and may own stock options or other equity incentive awards in, Lexicon Pharmaceuticals. J. Jackson and L. Law are former employees of Lexicon Pharmaceuticals. The authors have indicated that they have no other conflicts of interest with regard to the content of this article.

Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.